On Friday, Fulcrum Therapeutics Inc (NASDAQ: FULC) was 6.42% up from the session before settling in for the closing price of $3.27. A 52-week range for FULC has been $2.87 – $13.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -1.10% over the past five years. When this article was written, the company’s average yearly earnings per share was at 82.53%. With a float of $52.73 million, this company’s outstanding shares have now reached $61.92 million.
Let’s look at the performance matrix of the company that is accounted for 76 employees. In terms of profitability, gross margin is 97.69%, operating margin of -40.15%, and the pretax margin is -24.79%.
Fulcrum Therapeutics Inc (FULC) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Fulcrum Therapeutics Inc stocks. The insider ownership of Fulcrum Therapeutics Inc is 15.49%, while institutional ownership is 82.06%. The most recent insider transaction that took place on May 07 ’24, was worth 1,831. In this transaction Principal Accounting Officer of this company sold 236 shares at a rate of $7.76, taking the stock ownership to the 11,571 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Vice President, Finance sold 4,884 for $11.72, making the entire transaction worth $57,219. This insider now owns 11,807 shares in total.
Fulcrum Therapeutics Inc (FULC) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 82.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.40% during the next five years compared to 1.09% growth over the previous five years of trading.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
You can see what Fulcrum Therapeutics Inc (FULC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 22.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
Fulcrum Therapeutics Inc (NASDAQ: FULC) saw its 5-day average volume 0.64 million, a negative change from its year-to-date volume of 1.02 million. As of the previous 9 days, the stock’s Stochastic %D was 19.48%. Additionally, its Average True Range was 0.45.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 8.47%, which indicates a significant decrease from 23.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 98.44% in the past 14 days, which was lower than the 168.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.53, while its 200-day Moving Average is $7.75. Nevertheless, the first resistance level for the watch stands at $3.57 in the near term. At $3.65, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.81. If the price goes on to break the first support level at $3.33, it is likely to go to the next support level at $3.17. The third support level lies at $3.09 if the price breaches the second support level.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
There are 62,154K outstanding shares of the company, which has a market capitalization of 217.15 million. As of now, sales total 2,810 K while income totals -97,340 K. Its latest quarter income was 80,000 K while its last quarter net income were 55,410 K.
